<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">DVR</journal-id>
<journal-id journal-id-type="hwp">spdvr</journal-id>
<journal-title>Diabetes &amp; Vascular Disease Research</journal-title>
<issn pub-type="ppub">1479-1641</issn>
<issn pub-type="epub">1752-8984</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1479164112441524</article-id>
<article-id pub-id-type="publisher-id">10.1177_1479164112441524</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Standl</surname><given-names>Eberhard</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Schnell</surname><given-names>Oliver</given-names></name>
</contrib>
<aff id="aff1-1479164112441524">Munich Diabetes Research Group, Helmholtz Centre Munich-Neuherberg, Germany</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1479164112441524">Eberhard Standl, Munich Diabetes Research Group, Helmholtz Centre Munich-Neuherberg, Ingolstaedter Landstrasse 1, DE-85764 Neuherberg, Germany. Email: <email>Eberhard.Standl@lrz.uni-muenchen.de</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>9</volume>
<issue>3</issue>
<fpage>163</fpage>
<lpage>169</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Alpha-glucosidase inhibitors have been available for clinical use for about 20 years. They have shown reasonably good efficacy comparable to other oral blood glucose lowering drugs and in some parts of the world are the most commonly prescribed oral diabetes medication, especially in Asian countries. Unlike as has been observed with some other blood glucose lowering agents, however, no adverse signals of potential cardiovascular harm have emerged in relation to their use. On the contrary, significant beneficial cardiovascular outcome results have been observed in the post-hoc analyses of randomised placebo-controlled trials with the alpha-glucosidase inhibitor acarbose. Targeting mainly postprandial hyperglycaemia, alpha-glucosidase inhibitors favourably affect several cardiovascular risk factors, such as obesity, hypertension and high glycaemic variability with little to no risk for hypoglycaemia. Furthermore, acarbose favourably affects endothelial dysfunction and carotid intima media thickening in humans and, in animal models, improves cardiac interstitial fibrosis and hypertrophy of cardiomyocytes. The ultimate determination of the cardiovascular effects of alpha-glucosidase inhibitors in terms of clinical outcomes awaits the results of ongoing long-term, randomised, placebo-controlled trials.</p>
</abstract>
<kwd-group>
<kwd>Alpha-glucosidase inhibitors</kwd>
<kwd>postprandial hyperglycaemia</kwd>
<kwd>glycaemic variability</kwd>
<kwd>myocardial infarction</kwd>
<kwd>STOP-NIDDM Trial</kwd>
<kwd>Acarbose Evaluation Trial</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1479164112441524" sec-type="intro">
<title>Introduction</title>
<p>The golden paradigm to reduce cardiovascular (CV) complications in patients with diabetes mellitus remains a multifactorial approach based on therapeutic lifestyle management, targeting hypertension, dyslipidaemia, hyperglycaemia and hypercoagulability.<sup><xref ref-type="bibr" rid="bibr1-1479164112441524">1</xref></sup> In recent years, however, evidence has emerged that intensification of blood pressure and glucose control therapies yield no clear CV benefits and, in some cases, may also cause CV harm,<sup><xref ref-type="bibr" rid="bibr2-1479164112441524">2</xref><xref ref-type="bibr" rid="bibr3-1479164112441524"/><xref ref-type="bibr" rid="bibr4-1479164112441524"/><xref ref-type="bibr" rid="bibr5-1479164112441524"/><xref ref-type="bibr" rid="bibr6-1479164112441524"/>–<xref ref-type="bibr" rid="bibr7-1479164112441524">7</xref></sup> especially in patients with pre-existing CV disease.<sup><xref ref-type="bibr" rid="bibr2-1479164112441524">2</xref><xref ref-type="bibr" rid="bibr3-1479164112441524"/><xref ref-type="bibr" rid="bibr4-1479164112441524"/><xref ref-type="bibr" rid="bibr5-1479164112441524"/><xref ref-type="bibr" rid="bibr6-1479164112441524"/>–<xref ref-type="bibr" rid="bibr7-1479164112441524">7</xref></sup> Looking more specifically at various glucose-lowering drugs, it was found that treatment with some of them such as rosiglitazone,<sup><xref ref-type="bibr" rid="bibr8-1479164112441524">8</xref></sup> most sulfonylureas and even insulin might be associated with a higher risk of CV complications, at least when compared with metformin treatment.<sup><xref ref-type="bibr" rid="bibr9-1479164112441524">9</xref><xref ref-type="bibr" rid="bibr10-1479164112441524"/>–<xref ref-type="bibr" rid="bibr11-1479164112441524">11</xref></sup> For example, a large nationwide epidemiological study in Denmark has recently reiterated these concerns about a potentially increased mortality and CV risk associated with some sulphonylureas.<sup><xref ref-type="bibr" rid="bibr12-1479164112441524">12</xref></sup></p>
<p>This paper attempts to evaluate the case of alpha-glucosidase inhibitors, i.e. acarbose, voglibose and miglitol, which have been available as oral anti-diabetic drugs since the early 1990s.<sup><xref ref-type="bibr" rid="bibr13-1479164112441524">13</xref>,<xref ref-type="bibr" rid="bibr14-1479164112441524">14</xref></sup> Indeed, in some Asian countries with large diabetic populations, such as China, this class of drugs (especially acarbose) has become the most commonly prescribed glucose-lowering medication.<sup><xref ref-type="bibr" rid="bibr15-1479164112441524">15</xref></sup> Given the penetrant uptake of the alpha- glucosidase inhibitors and the availability of generic formulations in some cases, the issue of their CV affects is of practical importance.</p>
<sec id="section2-1479164112441524">
<title>Mode of action, dosing, efficacy</title>
<p>Alpha-glucosidases in the brush-border of the small intestine are competitively inhibited by the pseudo-carbohydrates acarbose, voglibose or miglitol. This inhibition delays digestion of complex carbohydrates in the upper small bowel and subsequently retards absorption of glucose and ‘blunts’ postprandial hyperglycaemia (<xref ref-type="fig" rid="fig1-1479164112441524">Figure 1</xref>).<sup><xref ref-type="bibr" rid="bibr13-1479164112441524">13</xref>,<xref ref-type="bibr" rid="bibr14-1479164112441524">14</xref>,<xref ref-type="bibr" rid="bibr16-1479164112441524">16,17</xref></sup> Intact acarbose is poorly absorbed and is excreted in the faeces, mostly intact but with up to 30% undergoing metabolism predominantly via fermentation by colonic microbiota.<sup><xref ref-type="bibr" rid="bibr13-1479164112441524">13</xref>,<xref ref-type="bibr" rid="bibr14-1479164112441524">14</xref>,<xref ref-type="bibr" rid="bibr16-1479164112441524">16</xref></sup> Similarly, voglibose is slowly and poorly absorbed and rapidly excreted in stools,<sup><xref ref-type="bibr" rid="bibr14-1479164112441524">14</xref></sup> with no metabolites identified to date.<sup><xref ref-type="bibr" rid="bibr18-1479164112441524">18</xref></sup> In contrast, miglitol is fully absorbed in the gut and cleared unchanged by the kidneys.<sup><xref ref-type="bibr" rid="bibr19-1479164112441524">19</xref></sup></p>
<fig id="fig1-1479164112441524" position="float">
<label>Figure 1.</label>
<caption>
<p>Acarbose acts non-systemically to delay carbohydrate absorption.</p>
</caption>
<graphic xlink:href="10.1177_1479164112441524-fig1.tif"/>
</fig>
<p>Adaptive changes in the lower smaller intestine, which may take several weeks to occur following initiation of therapy with alpha-glucosidase inhibitors, ensure full carbohydrate absorption, mitigate initial gastrointestinal side effects, such as abdominal distension, flatulence or diarrhoea, and also seem to be associated with a higher endogenous stimulation of glucagon-like peptide-1 (GLP-1).<sup><xref ref-type="bibr" rid="bibr16-1479164112441524">16</xref>,<xref ref-type="bibr" rid="bibr17-1479164112441524">17</xref></sup> In the context of this adaptation and the interval gastrointestinal side effects, it is advisable to pursue a dosing concept of ‘start low, go slow’. The average effective doses are 100 mg tid for acarbose, 0.2 mg tid for voglibose and 50 mg tid for miglitol.<sup><xref ref-type="bibr" rid="bibr13-1479164112441524">13</xref>,<xref ref-type="bibr" rid="bibr14-1479164112441524">14</xref></sup></p>
<p>In terms of glucose-lowering efficacy, acarbose is the most extensively evaluated agent. A Cochrane systematic review (<xref ref-type="fig" rid="fig2-1479164112441524">Figure 2</xref>)<sup><xref ref-type="bibr" rid="bibr20-1479164112441524">20</xref></sup> confirmed a placebo-subtracted decrease of HbA1c with acarbose therapy of 0.8% (95% confidence intervals (CI) 0.64–0.90), a 2.3 mmol/l reduction in postprandial glucose (95% CI 1.92–2.73), and a 1.1 mmol/l reduction in fasting glucose (95% CI 0.83–1.35). Comparable efficacy seems to be apparent from studies with voglibose and miglitol.<sup><xref ref-type="bibr" rid="bibr18-1479164112441524">18</xref>,<xref ref-type="bibr" rid="bibr19-1479164112441524">19</xref></sup></p>
<fig id="fig2-1479164112441524" position="float">
<label>Figure 2.</label>
<caption>
<p>Acarbose is an effective monotherapy for type 2 diabetes.<sup><xref ref-type="bibr" rid="bibr20-1479164112441524">20</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1479164112441524-fig2.tif"/>
</fig>
<p>Head to head comparisons have been performed against metformin, most sulphonylureas and meglitinides and the dipeptidyl-peptidase-4(DPP4) inhibitors.<sup><xref ref-type="bibr" rid="bibr21-1479164112441524">21</xref><xref ref-type="bibr" rid="bibr22-1479164112441524"/>–<xref ref-type="bibr" rid="bibr23-1479164112441524">23</xref></sup> In summary, the blood glucose-lowering potency as assessed by HbA1c measurements has been largely found comparable to those drugs, with an edge in favour of metformin in some studies. Of course, by their mode of action, the predominant blood-glucose lowering of alpha-glucosidase inhibitors occurs postprandially.<sup><xref ref-type="bibr" rid="bibr13-1479164112441524">13</xref>,<xref ref-type="bibr" rid="bibr14-1479164112441524">14</xref>,<xref ref-type="bibr" rid="bibr19-1479164112441524">19</xref><xref ref-type="bibr" rid="bibr20-1479164112441524"/><xref ref-type="bibr" rid="bibr21-1479164112441524"/><xref ref-type="bibr" rid="bibr22-1479164112441524"/>–<xref ref-type="bibr" rid="bibr23-1479164112441524">23</xref></sup></p>
</sec>
<sec id="section3-1479164112441524">
<title>Epidemiological and pathogenetic links of postprandial hyperglycaemia to CV disease</title>
<p>This postprandial aspect of action as seen with alpha- glucosidase inhibitors seems to be of importance. Compelling evidence has been accumulated over the last 20 years that elevated postprandial glucose values, even in the high non-diabetic impaired glucose tolerance (IGT) range, contribute to an approximately three-fold increase in the risk of developing coronary heart disease or other major adverse CV event.<sup><xref ref-type="bibr" rid="bibr24-1479164112441524">24</xref></sup> Controversy, however, exists whether elevated fasting plasma glucose and post-load glucose contribute differently to all-cause mortality or CV outcomes, respectively. A meta-analysis of Coutinho, et al. has suggested that both parameters contribute more or less equally,<sup><xref ref-type="bibr" rid="bibr25-1479164112441524">25</xref></sup> in contrast with publications, for example, from the DECODE,<sup><xref ref-type="bibr" rid="bibr26-1479164112441524">26</xref></sup> DECODA<sup><xref ref-type="bibr" rid="bibr27-1479164112441524">27</xref></sup> or Funagata<sup><xref ref-type="bibr" rid="bibr28-1479164112441524">28</xref></sup> studies that seem to support a unique role of postprandial hyperglycaemia contributing to CV risk. The ongoing prospective AusDiab Study, a cohort study of approximately 10,000 people across Australia with baseline glucose tolerance testing, has indicated a graded association between baseline glycaemic indices and subsequent CV clinical events and mortality over approximately 5-years of study follow-up, with similar model performance using impaired fasting glucose or IGT classifications.<sup><xref ref-type="bibr" rid="bibr29-1479164112441524">29</xref>,<xref ref-type="bibr" rid="bibr30-1479164112441524">30</xref></sup> The observational CAPRI study in overtly diabetic patients diet-treated or on oral glucose-lowering therapy has described an additional relationship between the maximal postprandial blood glucose peak and carotid intima-media thickness above and beyond the association observed with HbA1c.<sup><xref ref-type="bibr" rid="bibr31-1479164112441524">31</xref></sup> Furthermore, the Diabetes Intervention Study<sup><xref ref-type="bibr" rid="bibr32-1479164112441524">32</xref></sup> and the San Luigi Gonzaga Study<sup><xref ref-type="bibr" rid="bibr33-1479164112441524">33</xref></sup> investigators have reported specific associations between postprandial glucose concentrations and risk for subsequent CV events, such as myocardial infarction, in patients with type 2 diabetes.</p>
<p>A serious limitation of these epidemiological studies is that most often postprandial hyperglycaemia was not measured, but rather glycaemia after an oral glucose load with 75 g glucose was evaluated. It is noteworthy, therefore, that although the 2-h glucose values after an oral glucose load are closely correlated with the 2-h values after a standardised meal, the correlation with postprandial blood glucose experienced in the ambulatory setting are much more variable.<sup><xref ref-type="bibr" rid="bibr34-1479164112441524">34</xref></sup> Continuous glucose monitoring with sensors (CGMS) is probably a necessary prerequisite for studies trying to elucidate the specific impact of postprandial glycaemic parameters on CV outcomes, especially when it comes to glycaemic variability.<sup><xref ref-type="bibr" rid="bibr24-1479164112441524">24</xref></sup> This approach has been applied in a number of pathophysiological studies.<sup><xref ref-type="bibr" rid="bibr24-1479164112441524">24</xref></sup></p>
<p>As discussed recently, acute increases of blood glucose concentrations and fluctuating glucose levels with high peaks may induce haemodynamic alterations and are associated with endothelial dysfunction and signs of oxidative stress,<sup><xref ref-type="bibr" rid="bibr24-1479164112441524">24</xref>,<xref ref-type="bibr" rid="bibr35-1479164112441524">35</xref></sup> even in non-diabetic patients. The seminal work of Monnier et al. has shown that using CGMS in patients with type 2 diabetes, the urinary excretion of 8-isoprostanes as a sign of oxidative stress is closely correlated with the post-meal glucose levels and even more so with the maximal glucose excursions, in contrast to no such correlation with the HbA1c value or the mean glucose concentration.<sup><xref ref-type="bibr" rid="bibr36-1479164112441524">36</xref></sup> Ceriello et al. have used a model of generating glucose fluctuations by glucose infusion both in diabetic and non- diabetic subjects.<sup><xref ref-type="bibr" rid="bibr35-1479164112441524">35</xref></sup> They found a very close association of the glucose peaks with a decrease of the flow-mediated dilation of the forearm and an increase of nitrotyrosine, which reflects oxidative stress at the mitochondrial level.</p>
<p>Finally, Ceriello et al. went on to <italic>in vitro</italic> studies using human endothelial cells and exposing them to various glucose patterns, i.e. normal or constantly high glucose for 21 d vs. oscillating high and normal glucose for 21 d vs. oscillating high and low or permanently high glucose for 14 d followed by normal glucose by 7 d.<sup><xref ref-type="bibr" rid="bibr37-1479164112441524">37</xref></sup> They consistently showed the highest up-regulation of pathways related to apoptosis; at the gene transcription level, the highest generation of oxidative stress markers and DNA damage; and the highest reactive oxygen species accumulation with oscillating glucose concentrations. These alterations could not be restored to normal despite normalisation of glucose levels, suggesting thus a metabolic memory of human endothelial cells.<sup><xref ref-type="bibr" rid="bibr37-1479164112441524">37</xref></sup></p>
<p>So, in all, impressive evidence has been accumulated for the case of postprandial hyperglycaemia and fluctuating glucose concentrations with peaks as a pathophysiological link to disordered vascular reactions of large blood vessels and as a risk predictor for CV complications longer term.</p>
</sec>
<sec id="section4-1479164112441524">
<title>Intervening on postprandial hyperglycaemia: Acute and longer-term vascular effects</title>
<p>Measuring endothelial function at the myocardial level with positron emission tomography (PET) technology in insulin-requiring diabetic patients and targeting postprandial hyperglycaemia with various kinds of insulin regimens, a clear proof of principle could be obtained.<sup><xref ref-type="bibr" rid="bibr38-1479164112441524">38</xref></sup> When postprandial hyperglycaemia was abolished, myocardial blood flow was restored to normal, with paradoxical vasoconstriction with more marked postprandial hyperglycaemia evident.<sup><xref ref-type="bibr" rid="bibr38-1479164112441524">38</xref></sup> Similarly, using acarbose to target postprandial hyperglycaemia in non-insulin requiring diabetic subjects, forearm flow-mediated dilation improved significantly in two separate studies.<sup><xref ref-type="bibr" rid="bibr39-1479164112441524">39</xref>,<xref ref-type="bibr" rid="bibr40-1479164112441524">40</xref></sup> This was in contrast to a 3-month study of nateglinide treatment to assess postprandial hyperglycaemia and its association with myocardial blood flow measured with PET at baseline and follow-up.<sup><xref ref-type="bibr" rid="bibr41-1479164112441524">41</xref></sup> Withholding the drug on the day of PET evaluation, no change of myocardial flow parameters could be demonstrated. On the other hand, there was also rather little effect on postprandial hyperglycaemia.<sup><xref ref-type="bibr" rid="bibr41-1479164112441524">41</xref></sup> So, not all drug interventions of postprandial hyperglycaemia are equally effective at the vascular level and some drugs, such as acarbose, may show a unique effectiveness. This was also supported by animal studies in which exposure to acarbose was associated both with prevention of cardiac interstitial fibrosis and cardiomyocyte hypertrophy in a model of intermittent hypoxia.<sup><xref ref-type="bibr" rid="bibr42-1479164112441524">42</xref></sup></p>
<p>The landmark Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial evaluated the efficacy of 3 years of treatment with acarbose vs. placebo in preventing the transition to overt diabetes among 1429 patients with IGT.<sup><xref ref-type="bibr" rid="bibr43-1479164112441524">43</xref></sup> Targeting postprandial hyperglycaemia with acarbose was not only found to be associated with a 36% reduction of new onset diabetes, but also with a highly significant reduction of myocardial infarction (1 vs. 12, <italic>p</italic> = 0.0226) and any CV event (15 vs. 32, <italic>p</italic> = 0.0326) as assessed by a post hoc analysis of secondary outcomes (<xref ref-type="fig" rid="fig3-1479164112441524">Figure 3</xref>).<sup><xref ref-type="bibr" rid="bibr44-1479164112441524">44</xref></sup> In addition, new onset hypertension was significantly reduced with acarbose.<sup><xref ref-type="bibr" rid="bibr44-1479164112441524">44</xref></sup> In a subgroup of patients in the STOP-NIDDM trial in whom carotid intima-media-thickness was assessed, reduced thickening was observed under acarbose treatment over time.<sup><xref ref-type="bibr" rid="bibr45-1479164112441524">45</xref></sup> Consistent with these findings, another post hoc meta-analysis of seven randomised trials with acarbose in 2180 patients with type 2 diabetes and a follow-up of 1 year or longer (MeRia Study),<sup><xref ref-type="bibr" rid="bibr46-1479164112441524">46</xref></sup> likewise revealed a significant decrease of myocardial infarction (9 vs. 19, <italic>p</italic> = 0.012) and any CV event ( 76 vs. 88, <italic>p</italic> = 0.006). Similar to the observations in STOP-NIDDM, a significant reduction of blood pressure was also observed in the acarbose-treated patients in the MeRia Study,<sup><xref ref-type="bibr" rid="bibr46-1479164112441524">46</xref></sup> a phenomenon seen in another randomised controlled trial over 6 months in comparison with glibenclamide.<sup><xref ref-type="bibr" rid="bibr47-1479164112441524">47</xref></sup></p>
<fig id="fig3-1479164112441524" position="float">
<label>Figure 3.</label>
<caption>
<p>STOP-NIDDM trial: Lower incidence of cardiovascular events in acarbose treated patients.</p>
<p>Source: reproduced with permission of the American Medical Association, from Chiasson et al.<sup><xref ref-type="bibr" rid="bibr44-1479164112441524">44</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1479164112441524-fig3.tif"/>
</fig>
<p>Voglibose has also been evaluated in a randomised trial in terms of diabetes prevention in 1780 IGT subjects. A close to 50% reduction (multivariate analysis, hazard ratio, 0.512, CI 0.360–0.727, <italic>p</italic> = 0.0002) was found after 1 year, but no CV outcome data have been reported so far.<sup><xref ref-type="bibr" rid="bibr48-1479164112441524">48</xref></sup></p>
<p>Other randomised clinical trials seeking to specifically target postprandial hyperglycaemia have been less successful in improving CV outcomes, such as the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial<sup><xref ref-type="bibr" rid="bibr49-1479164112441524">49</xref></sup> or the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) Trial.<sup><xref ref-type="bibr" rid="bibr50-1479164112441524">50</xref></sup> In NAVIGATOR, the previously mentioned short-acting insulin secretagogue nateglinide compared with placebo was assessed in 9306 subjects with IGT and elevated risk for CV disease over 6 years. Nateglinide had no effect on incident diabetes risk nor CV risk and, when participants underwent oral glucose tolerance testing without the study drug on the day of testing, there was no decrease in 2-h glucose levels.<sup><xref ref-type="bibr" rid="bibr49-1479164112441524">49</xref></sup> Similarly, the HEART2D trial assessed prandial vs. basal insulin treatment in 1115 patients with type 2 diabetes following acute myocardial infarction<sup><xref ref-type="bibr" rid="bibr50-1479164112441524">50</xref></sup> and failed to achieve the per-protocol intended postprandial decrease of blood glucose and was an essentially negative trial in terms of improving CV outcomes. So, while these trials were negative with regard to the principal efficacy assessments, the failure within each trial to achieve the targeted postprandial glucose goals maintains the viability of the concept of potential CV efficacy with targeted postprandial glucose modulation and support ongoing assessments of the alpha-glucosidase inhibitors or other drugs similarly effective at modifying this parameter. Although intriguing, the data to date with regard to the CV safety and efficacy of existing alpha-glucosidase inhibitors are not definitive due to the extremely few CV events to analyse across the databases available.</p>
<p>Definitive evaluation of the CV effects of treatment with acarbose is underway in the ongoing Acarbose Cardiovascular Evaluation (ACE) Trial. The trial comprises 7500 patients in China with IGT and who are at least 3 months out from a prior myocardial infarction randomised to acarbose treatment vs. placebo. The trial is designed with co-primary endpoints of (a) prevention of diabetes and (b) major adverse CV events.<sup><xref ref-type="bibr" rid="bibr51-1479164112441524">51</xref></sup></p>
</sec>
<sec id="section5-1479164112441524">
<title>Recent clinical studies with alpha-glucosidase inhibitors</title>
<p>As already mentioned, acarbose remains the most widely studied drug of the class. It can be administered as mono-therapy or in combination with any other blood glucose-lowering drug, including insulin, as has been recently demonstrated again in a large-scale, observational study enrolling some 15,000 patients in China, Taiwan, the Middle-East, Morocco, Poland, Indonesia, Pakistan and the Philippines and with a follow-up of up to 3 years.<sup><xref ref-type="bibr" rid="bibr52-1479164112441524">52</xref></sup> It seems to offer specific advantages in terms of attenuating postprandial hyperglycaemia, glucose variability, hypoglycaemia and weight gain.<sup><xref ref-type="bibr" rid="bibr52-1479164112441524">52</xref></sup> A notable weight decrease was seen with acarbose over time in all treatment groups (mono-therapy, combination with metformin or sulfonylureas or insulin) despite a 1% lower HbA1c level. Mild gastrointestinal side effects, however, were apparent in a small minority of patients, which subsided with increasing duration of follow-up. In another study of patients with metformin-treated type 2 diabetes with continuous glucose monitoring used, randomised treatment with acarbose vs. glibenclamide, a comparable decrease of HbA1c was observed between the groups, but a much smaller intra-day and inter-day glucose variability was seen with acarbose. This effect was mainly due to a flattening of postprandial hyperglycaemia.<sup><xref ref-type="bibr" rid="bibr53-1479164112441524">53</xref></sup> Several episodes of hypoglycaemia occurred with glibenclamide during the 12-week evaluation period, in contrast to none with acarbose. Body weight decreased with acarbose by 1.4 kg and showed a tendency to increase with glibenclamide.<sup><xref ref-type="bibr" rid="bibr53-1479164112441524">53</xref></sup></p>
<p>In terms of preventing weight gain, acarbose was also highly effective in a 20-week placebo-controlled, randomised trial in patients who were newly started on insulin therapy. In this study, acarbose was superior in decreasing HbA1c and postprandial insulin levels.<sup><xref ref-type="bibr" rid="bibr54-1479164112441524">54</xref></sup> Finally, in a head to head comparison with the DPP4 inhibitor vildagliptin, acarbose was similarly effective in blood glucose lowering, yet superior in decreasing body weight.<sup><xref ref-type="bibr" rid="bibr22-1479164112441524">22</xref></sup></p>
<p>So in summary, clinical studies evaluating acarbose indicate a good glycaemic efficacy across all stages and all treatment options of type 2 diabetes. Acarbose seems to influence the CV risk factor profile positively, in particular by virtue of its excellent effect on weight control without the risk of hypoglycaemia. Hypoglycaemia in turn has been found to be a significant predictor of CV mortality in several of the recent intervention trials in type 2 diabetes.<sup><xref ref-type="bibr" rid="bibr2-1479164112441524">2</xref><xref ref-type="bibr" rid="bibr3-1479164112441524"/>–<xref ref-type="bibr" rid="bibr4-1479164112441524">4</xref></sup> In addition, the emerging CV risk constellations of postprandial hyperglycaemia and high glucose variability are clearly attenuated by acarbose.</p>
</sec>
<sec id="section6-1479164112441524">
<title>Perspectives</title>
<p>Twenty years after introduction of alpha-glucosidase inhibitors into the therapy of type 2 diabetes, still new discoveries can be made. In view of the recent issue of potential CV harm caused by some blood glucose-lowering agents, it is reassuring that no such signals have emerged in the context of the use of alpha-glucosidase inhibitors. On the contrary, significant beneficial CV outcome effects have been observed in the STOP-NIDDM Trial<sup><xref ref-type="bibr" rid="bibr43-1479164112441524">43</xref><xref ref-type="bibr" rid="bibr44-1479164112441524"/>–<xref ref-type="bibr" rid="bibr45-1479164112441524">45</xref></sup> and in a post-hoc analysis of randomised placebo-controlled trials with acarbose.<sup><xref ref-type="bibr" rid="bibr46-1479164112441524">46</xref></sup> Furthermore, CV risk factors such as obesity, hypertension, postprandial hyperglycaemia, high glucose variability seem to be influenced favourably. In contrast to other treatment options of blood glucose lowering, there is no risk of hypoglycaemia, which has turned out to also be a risk predictor of CV mortality in its own right. The ultimate proof for a significant CV benefit of acarbose is hoped to come from the ongoing ACE Trial.<sup><xref ref-type="bibr" rid="bibr51-1479164112441524">51</xref></sup> Since many of the ongoing randomised, long-term trials looking into CV outcomes in relation to the use of DPP4 inhibitors or the GLP-1 analogues, as discussed elsewhere in this issue by Jose and Inzucchi which also mainly target postprandial hyperglycaemia, it will remain interesting how these trials will compare with the ACE Trial.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This activity has been supported by an educational grant of the Association for the Support of International Scientific Communication in Diabetology e.V., Munich, Germany.</p>
</fn>
<fn fn-type="conflict">
<label>Conflicts of interest</label>
<p>Conflicts of interest for Professor Standl:</p>
<p>Task force: First Joint EASD/ESC Guidelines; DSMBs: PROActive, Navigator, ACE Trials; Investigator: studies initiated by Oxford Trial Unit, Bayer Schering, Menarini, Novartis, NovoNordisk, Sanofi-Aventis, Servier, MSD/Merck; Lecturing honoraria and consultation fees: Astra Zenica, Bayer, BMS, GSK, Johnson &amp; Johnson, Lilly, Menarini, Merck-Serono, MSD/Merck, Novartis, NovoNordisk, Rambaxi, Roche, Sanofi-Aventis, Servier, Takeda.</p>
<p>Conflicts of interest for Professor Schnell:</p>
<p>Lecturing honoraria and consultation fees: Bayer Schering Pharma.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1479164112441524">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ryden</surname><given-names>L</given-names></name>
<name><surname>Standl</surname><given-names>E</given-names></name>
<name><surname>Bartnik</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <collab>Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary</collab>. <article-title>The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)</article-title>. <source>Eur Heart J</source> <year>2007</year>; <volume>28</volume>: <fpage>88</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr2-1479164112441524">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerstein</surname><given-names>HC</given-names></name>
<name><surname>Miller</surname><given-names>ME</given-names></name>
<name><surname>Byington</surname><given-names>RP</given-names></name>
<etal/>
</person-group>. <article-title>Effects of intensive glucose lowering in type 2 diabetes</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>2545</fpage>–<lpage>2559</lpage>.</citation>
</ref>
<ref id="bibr3-1479164112441524">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ray</surname><given-names>KK</given-names></name>
<name><surname>Seshasai</surname><given-names>SR</given-names></name>
<name><surname>Wijesuriya</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials</article-title>. <source>Lancet</source> <year>2009</year>; <volume>373</volume>: <fpage>1765</fpage>–<lpage>1772</lpage>.</citation>
</ref>
<ref id="bibr4-1479164112441524">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turnbull</surname><given-names>FM</given-names></name>
<name><surname>Abraira</surname><given-names>C</given-names></name>
<name><surname>Anderson</surname><given-names>RJ</given-names></name>
<etal/>
</person-group>. <article-title>Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia</article-title> <year>2009</year>; <volume>52</volume>: <fpage>2288</fpage>–<lpage>2298</lpage>.</citation>
</ref>
<ref id="bibr5-1479164112441524">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cushman</surname><given-names>WC</given-names></name>
<name><surname>Evans</surname><given-names>GW</given-names></name>
<name><surname>Byington</surname><given-names>RP</given-names></name>
<etal/>
</person-group>. <article-title>Effects of intensive blood-pressure control in type 2 diabetes mellitus</article-title>. <source>N Engl J Med</source> <year>2010</year>; <volume>362</volume>: <fpage>1575</fpage>–<lpage>1585</lpage>.</citation>
</ref>
<ref id="bibr6-1479164112441524">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cooper-DeHoff</surname><given-names>RM</given-names></name>
<name><surname>Gong</surname><given-names>Y</given-names></name>
<name><surname>Handberg</surname><given-names>EM</given-names></name>
<etal/>
</person-group>. <article-title>Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease</article-title>. <source>JAMA</source> <year>2010</year>; <volume>304</volume>: <fpage>61</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr7-1479164112441524">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haller</surname><given-names>H</given-names></name>
<name><surname>Ito</surname><given-names>S</given-names></name>
<name><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr</suffix></name>
<etal/>
</person-group>. <article-title>Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes</article-title>. <source>N Engl J Med</source> <year>2011</year>; <volume>364</volume>: <fpage>907</fpage>–<lpage>917</lpage>.</citation>
</ref>
<ref id="bibr8-1479164112441524">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nissen</surname><given-names>SE</given-names></name>
<name><surname>Wolski</surname><given-names>K</given-names></name>
</person-group>. <article-title>Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>356</volume>: <fpage>2457</fpage>–<lpage>2471</lpage>.</citation>
</ref>
<ref id="bibr9-1479164112441524">
<label>9.</label>
<citation citation-type="book">
<collab>National Institute for Health and Clinical Excellence</collab>. <source>Type 2 diabetes: Newer agents</source>. <comment>NICE short clinical guideline 87</comment>. <publisher-loc>London</publisher-loc>: <publisher-name>NICE</publisher-name>, <year>2009</year>; pp. <fpage>1</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr10-1479164112441524">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Monami</surname><given-names>M</given-names></name>
<name><surname>Balzi</surname><given-names>D</given-names></name>
<name><surname>Lamanna</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality</article-title>. <source>Diabetes Metab Res Rev</source> <year>2007</year>; <volume>23</volume>: <fpage>479</fpage>–<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr11-1479164112441524">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mellbin</surname><given-names>LG</given-names></name>
<name><surname>Malmberg</surname><given-names>K</given-names></name>
<name><surname>Norhammar</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study</article-title>. <source>Diabetologia</source> <year>2011</year>; <volume>54</volume>: <fpage>1308</fpage>–<lpage>1317</lpage>.</citation>
</ref>
<ref id="bibr12-1479164112441524">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schramm</surname><given-names>TK</given-names></name>
<name><surname>Gislason</surname><given-names>GH</given-names></name>
<name><surname>Vaag</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study</article-title>. <source>Eur H J</source> <year>2011</year>; <volume>32</volume>: <fpage>1900</fpage>–<lpage>1908</lpage>.</citation>
</ref>
<ref id="bibr13-1479164112441524">
<label>13.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Lefebvre</surname><given-names>PJ</given-names></name>
<name><surname>Standl</surname><given-names>E</given-names></name>
</person-group>. <source>New aspects in diabetes. Treatment strategies with alpha-glucosidase inhibitors</source>. <publisher-loc>Berlin/New York</publisher-loc>: <publisher-name>Walter de Gruyter</publisher-name>, <year>1992</year>, pp. <fpage>1</fpage>–<lpage>294</lpage>.</citation>
</ref>
<ref id="bibr14-1479164112441524">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Desai</surname><given-names>A</given-names></name>
<name><surname>Tandon</surname><given-names>N</given-names></name>
</person-group>. <article-title>Diabetes mellitus: everyday practice</article-title>. <source>Natl Med J India</source> <year>2007</year>; <volume>20</volume>: <fpage>192</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr15-1479164112441524">
<label>15.</label>
<citation citation-type="web">
<collab>IMSPlus CHPA, IMS Global Services</collab>. <article-title>China Hospital Pharmaceutical Audit</article-title>. <comment>Quarterly Market Brief 2Q2009 and China Pharmaceutical Market Snapshot Q2/2011, <ext-link ext-link-type="uri" xlink:href="http://www.IMSHealth.com">www.IMSHealth.com</ext-link></comment> (<access-date>accessed 15 January 2012</access-date>).</citation>
</ref>
<ref id="bibr16-1479164112441524">
<label>16.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Bischoff</surname><given-names>H</given-names></name>
</person-group>. <article-title>Pharmacology of alpha-glucosidase-inhibitors</article-title>. In: <person-group person-group-type="editor">
<name><surname>Vasselli</surname><given-names>J</given-names></name>
<name><surname>Maggio</surname><given-names>C</given-names></name>
<name><surname>Scriabine</surname><given-names>A</given-names></name>
</person-group> (eds) <source>Drugs in development: alpha-glucosidase inhibition: potential use in diabetes</source>. <publisher-loc>Branford, CT, USA</publisher-loc>: <publisher-name>Neva Press</publisher-name>, <year>1993</year>, pp. <fpage>3</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr17-1479164112441524">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Qualmann</surname><given-names>C</given-names></name>
<name><surname>Nauck</surname><given-names>MA</given-names></name>
<name><surname>Holst</surname><given-names>JJ</given-names></name>
<etal/>
</person-group>. <article-title>Glucagon-like peptide 1 (7–36 amide) secretion in response to luminal sucrose from the upper and the lower gut. A study using alpha- glucosidase inhibition (acarbose)</article-title>. <source>Scand J Gastroenterol</source> <year>1995</year>; <volume>30</volume>: <fpage>892</fpage>–<lpage>896</lpage>.</citation>
</ref>
<ref id="bibr18-1479164112441524">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Göke</surname><given-names>B</given-names></name>
<name><surname>Fuder</surname><given-names>H</given-names></name>
<name><surname>Wieckhorst</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve</article-title>. <source>Digestion</source> <year>1995</year>; <volume>56</volume>: <fpage>493</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr19-1479164112441524">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Standl</surname><given-names>E</given-names></name>
<name><surname>Schernthaner</surname><given-names>G</given-names></name>
<name><surname>Rybka</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics</article-title>. <source>Diabetes Res Clin Pract</source> <year>2001</year>; <volume>52</volume>: <fpage>205</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr20-1479164112441524">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van de Laar</surname><given-names>FA</given-names></name>
<name><surname>Lucassen</surname><given-names>PL</given-names></name>
<name><surname>Akkermans</surname><given-names>RP</given-names></name>
<etal/>
</person-group>. <article-title>Alpha-glucosdase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta- analysis</article-title>. <source>Diabetes Care</source> <year>2005</year>; <volume>28</volume>: <fpage>154</fpage>–<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr21-1479164112441524">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanefeld</surname><given-names>M</given-names></name>
<name><surname>Schaper</surname><given-names>F</given-names></name>
</person-group>. <article-title>Acarbose: oral anti-diabetes drug with additional cardiovascular benefits</article-title>. <source>Expert Rev Cardiovasc Ther</source> <year>2008</year>; <volume>6</volume>: <fpage>153</fpage>–<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr22-1479164112441524">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pan</surname><given-names>C</given-names></name>
<name><surname>Yang</surname><given-names>W</given-names></name>
<name><surname>Barona</surname><given-names>JP</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial</article-title>. <source>Diabet Med</source> <year>2008</year>; <volume>25</volume>: <fpage>435</fpage>–<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr23-1479164112441524">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schnell</surname><given-names>O</given-names></name>
<name><surname>Chan</surname><given-names>J</given-names></name>
<name><surname>Josse</surname><given-names>RG</given-names></name>
</person-group>. <article-title>Therapeutic experience with acarbose in the treatment of type 2 diabetes</article-title>. <source>Diabetes Metab &amp; the Heart</source> <year>2009</year>; <volume>18</volume>: <fpage>409</fpage>–<lpage>415</lpage>.</citation>
</ref>
<ref id="bibr24-1479164112441524">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Standl</surname><given-names>E</given-names></name>
<name><surname>Schnell</surname><given-names>O</given-names></name>
<name><surname>Ceriello</surname><given-names>A</given-names></name>
</person-group>. <article-title>Postprandial hyperglycemia and glycemic variability. Should we care?</article-title> <source>Diabetes Care</source> <year>2011</year>; <volume>34</volume>(<supplement>Suppl 2</supplement>): <fpage>120</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr25-1479164112441524">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coutinho</surname><given-names>M</given-names></name>
<name><surname>Gerstein</surname><given-names>HC</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years</article-title>. <source>Diabetes Care</source> <year>1999</year>; <volume>22</volume>: <fpage>233</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr26-1479164112441524">
<label>26.</label>
<citation citation-type="journal">
<collab>The DECODE Study Group; European Diabetes Epidemiology Group</collab>. <article-title>Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnsotic criteria in Europe</article-title>. <source>Lancet</source> <year>1999</year>; <volume>354</volume>: <fpage>617</fpage>–<lpage>621</lpage>.</citation>
</ref>
<ref id="bibr27-1479164112441524">
<label>27.</label>
<citation citation-type="journal">
<collab>Nakagami T; DECODA Study Group</collab>. <article-title>Hyperglycemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin</article-title>. <source>Diabetologia</source> <year>2004</year>; <volume>47</volume>: <fpage>385</fpage>–<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr28-1479164112441524">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tominaga</surname><given-names>M</given-names></name>
<name><surname>Eguchi</surname><given-names>H</given-names></name>
<name><surname>Manaka</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study</article-title>. <source>Diabetes Care</source> <year>1999</year>; <volume>22</volume>: <fpage>920</fpage>–<lpage>924</lpage>.</citation>
</ref>
<ref id="bibr29-1479164112441524">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barr</surname><given-names>EL</given-names></name>
<name><surname>Zimmet</surname><given-names>PZ</given-names></name>
<name><surname>Welborn</surname><given-names>TA</given-names></name>
<etal/>
</person-group>. <article-title>Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)</article-title>. <source>Circulation</source> <year>2007</year>; <volume>116</volume>: <fpage>151</fpage>–<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr30-1479164112441524">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barr</surname><given-names>EL</given-names></name>
<name><surname>Boyko</surname><given-names>EJ</given-names></name>
<name><surname>Zimmet</surname><given-names>PZ</given-names></name>
<etal/>
</person-group>. <article-title>Continuous relationship between non-diabetic hyperglycemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study</article-title>. <source>Diabetologia</source> <year>2009</year>; <volume>52</volume>: <fpage>415</fpage>–<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr31-1479164112441524">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esposito</surname><given-names>K</given-names></name>
<name><surname>Ciotola</surname><given-names>M</given-names></name>
<name><surname>Carleo</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source> <year>2008</year>; <volume>93</volume>: <fpage>1345</fpage>–<lpage>1350</lpage>.</citation>
</ref>
<ref id="bibr32-1479164112441524">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanefeld</surname><given-names>M</given-names></name>
<name><surname>Fischer</surname><given-names>S</given-names></name>
<name><surname>Julius</surname><given-names>U</given-names></name>
<etal/>
</person-group>. <article-title>Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study. 11 year follow-up</article-title>. <source>Diabetologia</source> <year>1996</year>; <volume>39</volume>: <fpage>1577</fpage>–<lpage>1583</lpage>.</citation>
</ref>
<ref id="bibr33-1479164112441524">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cavalot</surname><given-names>F</given-names></name>
<name><surname>Pettrelli</surname><given-names>A</given-names></name>
<name><surname>Traversa</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study</article-title>. <source>J Clin Endocrinol Metab</source> <year>2006</year>; <volume>91</volume>: <fpage>813</fpage>–<lpage>819</lpage>.</citation>
</ref>
<ref id="bibr34-1479164112441524">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meier</surname><given-names>JJ</given-names></name>
<name><surname>Baller</surname><given-names>B</given-names></name>
<name><surname>Menge</surname><given-names>BA</given-names></name>
<etal/>
</person-group>. <article-title>Excess glycemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycemia and vice versa?</article-title> <source>Diabetes Obes Metab</source> <year>2009</year>; <volume>11</volume>: <fpage>213</fpage>–<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr35-1479164112441524">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ceriello</surname><given-names>A</given-names></name>
<name><surname>Esposito</surname><given-names>K</given-names></name>
<name><surname>Piconi</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients</article-title>. <source>Diabetes</source> <year>2008</year>; <volume>57</volume>: <fpage>1349</fpage>–<lpage>1354</lpage>.</citation>
</ref>
<ref id="bibr36-1479164112441524">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Monnier</surname><given-names>L</given-names></name>
<name><surname>Mas</surname><given-names>E</given-names></name>
<name><surname>Ginet</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Activation of oxidative stress by acute Glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes</article-title>. <source>JAMA</source> <year>2006</year>; <volume>295</volume>: <fpage>1681</fpage>–<lpage>1687</lpage>.</citation>
</ref>
<ref id="bibr37-1479164112441524">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schisano</surname><given-names>B</given-names></name>
<name><surname>Tripathi</surname><given-names>G</given-names></name>
<name><surname>McGee</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells</article-title>. <source>Diabetologia</source> <year>2011</year>; <volume>54</volume>: <fpage>1219</fpage>–<lpage>1226</lpage>.</citation>
</ref>
<ref id="bibr38-1479164112441524">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scognamiglio</surname><given-names>R</given-names></name>
<name><surname>Negut</surname><given-names>C</given-names></name>
<name><surname>de Kreutzenberg</surname><given-names>SV</given-names></name>
<etal/>
</person-group>. <article-title>Effect of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients</article-title>. <source>Diabetes Care</source> <year>2006</year>; <volume>29</volume>: <fpage>95</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr39-1479164112441524">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wascher</surname><given-names>TC</given-names></name>
<name><surname>Schmoelzer</surname><given-names>I</given-names></name>
<name><surname>Wiegratz</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Reduction of postchallenge hyperglycemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance</article-title>. <source>Eur J Clin Invest</source> <year>2005</year>; <volume>35</volume>: <fpage>551</fpage>–<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr40-1479164112441524">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimabukuro</surname><given-names>M</given-names></name>
<name><surname>Higa</surname><given-names>N</given-names></name>
<name><surname>Chinen</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Effects of a single administration of acarbose on post-prandial glucose excursions and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study</article-title>. <source>J Clin Endocrinol Metab</source> <year>2006</year>; <volume>91</volume>: <fpage>837</fpage>–<lpage>842</lpage>.</citation>
</ref>
<ref id="bibr41-1479164112441524">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bengel</surname><given-names>FM</given-names></name>
<name><surname>Abletshauser</surname><given-names>C</given-names></name>
<name><surname>Neverve</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus – a randomized study using positron emission tomography</article-title>. <source>Diabetic Med</source> <year>2004</year>; <volume>22</volume>: <fpage>158</fpage>–<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr42-1479164112441524">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miyamura</surname><given-names>M</given-names></name>
<name><surname>Schnell</surname><given-names>O</given-names></name>
<name><surname>Yamashita</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Effects of acarbose on the acceleration of postprandial hyperglycemia-induced pathological changes induced by intermittent hypoxia in lean mice</article-title>. <source>J Pharmacol Sci</source> <year>2010</year>; <volume>114</volume>: <fpage>32</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr43-1479164112441524">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chiasson</surname><given-names>JL</given-names></name>
<name><surname>Josse</surname><given-names>RG</given-names></name>
<name><surname>Gomis</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial</article-title>. <source>Lancet</source> <year>2002</year>; <volume>359</volume>: <fpage>2072</fpage>–<lpage>2077</lpage>.</citation>
</ref>
<ref id="bibr44-1479164112441524">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chiasson</surname><given-names>JL</given-names></name>
<name><surname>Josse</surname><given-names>RG</given-names></name>
<name><surname>Gomis</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impairedglucose tolerance: the STOP-NIDDM trial</article-title>. <source>JAMA</source> <year>2003</year>; <volume>290</volume>: <fpage>486</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr45-1479164112441524">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanefeld</surname><given-names>M</given-names></name>
<name><surname>Chiasson</surname><given-names>JL</given-names></name>
<name><surname>Koehler</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance</article-title>. <source>Stroke</source> <year>2004</year>; <volume>25</volume>: <fpage>10</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr46-1479164112441524">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanefeld</surname><given-names>M</given-names></name>
<name><surname>Cagatay</surname><given-names>M</given-names></name>
<name><surname>Petrowitsch</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies</article-title>. <source>Eur Heart J</source> <year>2004</year>; <volume>25</volume>: <fpage>10</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr47-1479164112441524">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenthal</surname><given-names>JH</given-names></name>
<name><surname>Mauersberger</surname><given-names>H</given-names></name>
</person-group>. <article-title>Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and typ 2 diabetes mellitus</article-title>. <source>Clin Drug Invest</source> <year>2002</year>; <volume>22</volume>: <fpage>695</fpage>–<lpage>701</lpage>.</citation>
</ref>
<ref id="bibr48-1479164112441524">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kawamori</surname><given-names>R</given-names></name>
<name><surname>Tajima</surname><given-names>N</given-names></name>
<name><surname>Iwamoto</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Voglibose for prevention of type 2 diabetes mellitus: a randomized, double-blind tiral in Japanese individuals with impaired glucose tolerance</article-title>. <source>Lancet</source> <year>2009</year>; <volume>373</volume>: <fpage>1607</fpage>–<lpage>1614</lpage>.</citation>
</ref>
<ref id="bibr49-1479164112441524">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holman</surname><given-names>RR</given-names></name>
<name><surname>Haffner</surname><given-names>SM</given-names></name>
<name><surname>McMurray</surname><given-names>JJ</given-names></name>
<etal/>
</person-group>. <collab>NAVIGATOR Study Group</collab>. <article-title>Effect of nateglinide on the incidence of diabetes and cardiovascular events</article-title>. <source>N Engl J Med</source> <year>2010</year>; <volume>362</volume>: <fpage>1463</fpage>–<lpage>1476</lpage>.</citation>
</ref>
<ref id="bibr50-1479164112441524">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raz</surname><given-names>I</given-names></name>
<name><surname>Wilson</surname><given-names>PWF</given-names></name>
<name><surname>Strojek</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Effects of prandial versus fasting glycemia On cardiovascular outcomes in type 2 diabetes: the HEART2D trial</article-title>. <source>Diabetes Care</source> <year>2009</year>; <volume>32</volume>: <fpage>381</fpage>–<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr51-1479164112441524">
<label>51.</label>
<citation citation-type="web">
<collab>Acarbose Cardiovascular Evaluation</collab>, <comment>launched</comment> <day>11</day> <month>April</month> <year>2008</year>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.dtu.ox.ac.uk/ace/index">http://www.dtu.ox.ac.uk/ace/index</ext-link></comment> (<access-date>accessed 15 December 2011</access-date>).</citation>
</ref>
<ref id="bibr52-1479164112441524">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>C</given-names></name>
<name><surname>Hung</surname><given-names>Y-J</given-names></name>
<name><surname>Qamruddin</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>International Noninterventional study of acarbose treatment in patients with typ 2 diabetes mellitus</article-title>. <source>Diabetes Res Clin Pract</source> <year>2011</year>; <volume>92</volume>: <fpage>57</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr53-1479164112441524">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>S-D</given-names></name>
<name><surname>Wang</surname><given-names>J-S</given-names></name>
<name><surname>Hsu</surname><given-names>S-R</given-names></name>
<etal/>
</person-group>. <article-title>The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared withsulfonyurea in Taiwanese type 2 diabetic patients inadequatelycontrolled with metformin: Preliminary data</article-title>. <source>J Diabet Complications</source>. <comment>Epub ahead of print 1 August 2011</comment>, DOI: 10.1016/j.jdiacomp. 2011.06.004<pub-id pub-id-type="doi">10.1016/j.jdiacomp. 2011.06.004</pub-id>.</citation>
</ref>
<ref id="bibr54-1479164112441524">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schnell</surname><given-names>O</given-names></name>
<name><surname>Mertes</surname><given-names>G</given-names></name>
<name><surname>Standl</surname><given-names>E</given-names></name>
</person-group>. <article-title>Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy</article-title>. <source>Diabetes Obes Metab</source> <year>2007</year>; <volume>6</volume>: <fpage>853</fpage>–<lpage>858</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>